scPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and ...
Pharmaceuticals generated fourth quarter 2024 net FUROSCIX® revenue of $12.2 million, and full year 2024 revenue of $36.3 millionCash and cash ...
Hospital Healthcare Europe7 小时
Improving treatment pathways in muscle-invasive bladder cancer
Professors Rik Bryan and Nicholas James explain how an image-directed pathway for muscle-invasive bladder cancer improves ...
National Institute for Health and Care Excellence11 小时
In consultation: Guidance and quality standards
Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy [ID6369] Draft guidance Technology appraisal guidance 2 April ...